Minimal-invasive Therapie des benignen Prostatasyndroms

Magistro, G.; Stief, C. G. und Gratzke, C. (2016): Minimal-invasive Therapie des benignen Prostatasyndroms. In: Urologe, Bd. 55, Nr. 11: S. 1419-1432

Abstract

Novel minimally invasive treatment options for the management of male lower urinary tract symptoms (LUTS) due to bladder outlet obstruction (BOO) aim to provide equal efficacy compared to standard techniques with a more favourable safety profile. The preservation of all aspects of male sexual function including antegrade ejaculation is increasingly important to patients. It should be ideally performed in an outpatient setting under local anesthesia to assure a short recovery time. Novel injectables for intraprostatic application (botulinum neurotoxin A, NX-1207, PRX302) have emerged and first phase III results could not confirm the promising initial data. For mechanical devices like UroliftA (R) the early and mid-term benefits demonstrate a rapid and durable symptom relief without compromising sexual function. Novel innovative procedures like aquablation (AquaBeamA (R)) are entering the scene, but their feasibility, efficacy and safety still need to be addressed in randomized controlled trials.

• Dokumententyp: Zeitschriftenartikel
• Fakultät: Medizin
• Themengebiete: 600 Technik, Medizin, angewandte Wissenschaften > 610 Medizin und Gesundheit
• ISSN: 0340-2592
• Sprache: Deutsch